Business
BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer
52% of BriaCell’s most-recent 25-patient cohort* have surpassed the one-year survival mile...
About this update from Briacell Therapeutics Corp
[{"type":"text","content":"BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer\n\n\n\n\n\n\n 52% of BriaCell’s most-recent 25-patient cohort* have surpassed the one-year survival milestone, exceeding current standard of care in similar patients\n \n\n\n\n\n\n 11 patients remain alive as of recent contact, including one patient at 38.3 months and another at 30.3 months\n \n\n\n\n\n\n Survival benefit observed in heavily pre-treated patients, including those who failed treatment with checkpoint inhibitors (CPIs) and antibody-drug conjugates (ADCs)\n \n\n\n\n\n PHILADELPHIA and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, has reported updated survival data from its ongoing Phase 2 clinical study of Bria-IMT in patients with metastatic breast cancer (MBC).\n \n\n\n BriaCell’s most recent Phase 2 study cohort of 25 patients* achieved a 52% one-year survival rate (i.e. 52% of patients remained alive at least one year after starting on the study).\n \n\n 11 of these patients remain alive as of most recent contact, including one patient at 38.3 months and another at 30.3 months (see Table 1).\n \n\n Survival rate exceeds the survival expectations with the current standard of care therapies in similar patient populations (see Table 2).\n \n\n Notably, many patients had very advanced metastatic breast cancer, having already failed multiple prior lines of therapy including check point inhibitors (CPIs) and antibody-drug conjugates (ADCs) such as TRODELVY® - (sacituzumab govitecan-hziy) and ENHERTU® (fam-trastuzumab - deruxtecan-nxki).\n \n\n No treatment discontinuations attributed to Bria-IMT have been reported.\n \n\n\n\n\n\n Table 1: Select Long-Term Responders\n \n\n\n\n\n\n Patient\n \n\n\n\n Months Survival\n \n\n\n\n Age\n \n\n\n\n Prior Regimens\n \n\n\n\n Cycles of Bria-IMT\n \n\n\n\n\n 01-009\n \n\n 38.3\n \n\n 74\n \n\n 5\n \n\n 13\n \n\n\n\n 07-001\n \n\n 30.3\n \n\n 55\n \n\n 7; including ENHERTU\n \n\n 8\n \n\n\n\n 11-018\n \n\n 21.6\n \n\n 66\n \n\n 8\n \n\n 28\n \n\n\n\n 11-019\n \n\n 20.0\n \n\n 63\n \n\n 9; including TRODELVY\n \...